Endostatin, Active, Recombinant, Mouse

Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Angiogenesis accounts for the formation of vasculature into previously avascular organs such as brain and kidney. Angiogenic activity in the adult is required during the normal tissue repair, and for the remodeling of the female reproductive organs (ovulation and placental development). Certain pathological conditions, such as tumor growth and diabetic retinopathy, also require angiogenesis. \n\nRecent studies have identified several proteolytic fragments or cryptic domains of proteins that act as inhibitors of angiogenesis. These include fragments of plasminogen such as Angiostatin protein (kringles 1-4) and kringles 1-5, C-terminal proteolytic fragment of Collagen XVIII (Endostatin protein), the NC10 domain of collagen 15 (Restin), the C-terminal hemopexin-like domain of MMP-2 (PEX), the N-terminal fragment of prolactin, and the N-terminally truncated platelet factor. The 20kD fragment of Collagen XVIII known as Endostatin protein inhibits tumor progression and induction of endothelial cell apoptosis. Administration of Endostatin protein to mice bearing certain tumors caused tumor regression without the development of drug resistance. Endostatin protein also inhibited systemic angiogenesis, primary tumor growth, and the development of primary metastatic lesions. It also reduced the levels of antiapoptotic proteins Bcl-2 and Bcl-xL and an increase in apoptosis of endothelial cells.\n\nSource:\nRecombinant mouse Endostatin, expressed in Pichia pastoris.\n\nMolecular Weight:\n~20kD\n\nBiological Activity:\n10ug of Endostatin injected subcutaneously once daily for 11 days resulted in 76% inhibition growth of metastases in the B16BL6 murine metastasis model.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

E2296-10B2

Size

250ug

Form

Supplied as a lyophillized powder from 50mM sodium phosphate, 60mM sodium chloride, 17mM citric acid, pH6.2. Reconstitute in 250ul dH2O.

Purity

~95% (SDS-PAGE)

References

1. Peterson Te et al (1990) JBC 265, 6104-6111. 2. Forsgren m et al (1987) FEBS Lett. 213, 254-260. 3. Malinowski DP et al 1984) Biochemistry 23, 4243-4250. 4. O'Reilly MS et al (1994) Cell 79, 315-328. 5. Sim BK et al (1997) Cancer Res. 57, 1329-1334. 6. Wu Z et al (1997) BBRC 236, 651.